Home » Topics » Regulatory » NMPA

NMPA
RSS

Phase II trials of F-351 begin in China

June 12, 2015

Arteether amine maleate cleared to enter clinical studies in China

May 26, 2015

China FDA clears IND for development of DP-VPA through phase III for epilepsy

April 16, 2015

China approves Epidaza for peripheral T-cell lymphoma

Jan. 13, 2015

Sirnaomics files Chinese IND application for STP-705 for hypertrophic scars

Jan. 7, 2015

China publishes draft biosimilar guidance

Nov. 18, 2014

DC Bead approved in China for tumor embolization

Aug. 28, 2014

UC MSCs show potential in clinical study for SLE

July 30, 2014

China's regulatory authority approves phase II trials of F-351

July 3, 2014

Chinese fast track designation granted to epilepsy drug DP-VPA

June 11, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...